Compare Danaher Corporation (DHR) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs MPLX LP — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while MPLX LP trades at $56.3 (market cap $58.11B). The key difference: Danaher Corporation is far larger — about 2.6× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| DHR | MPLX | |
|---|---|---|
Market Cap | $152.87B | $58.11B |
Volume | 5,228,698 | 687,483 |
Sector | Health | Energy |
52-Week High | $242.05 | $60.51 |
52-Week Low | $161.91 | $47.80 |
Typical Hold Time | 69 Days | — |
Enterprise Value | $175.08B | $83.22B |
Dividend Yield | 0.74% | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
MPLX trades at $57.32, up 0.47% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, supported by $4.91B net income in 2025. Recent earnings show mixed results with a Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 11.3% upside potential.
The investment case balances strong cash flow generation and dividend stability against energy market volatility risks. MPLX's fee-based midstream model provides revenue resilience, though technical indicators suggest near-term pressure. The 67.86% buy rating consensus indicates Wall Street confidence in the company's ability to maintain distribution growth despite recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
